Clinical trial Archives

News and Trends 29 Sep 2022

Treatment for adults with chronic skin condition approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases […]

September 29, 2022 - 4 minutesmins - By Liza Laws

More News! 29 Sep 2022

Positive results from Eisai and Biogen Alzheimer’s trial

Eisai Co., Ltd. and Biogen Inc. have announced positive topline results from Eisai’s large global phase 3 confirmatory Clarity AD clinical trial of lecanemab to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Lecanemab is an […]

September 29, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 28 Sep 2022

Ilya Pharma enrols first patient in diabetic foot ulcer study

Ilya Pharma AB says the first patients have been enrolled in a phase II study for its lead candidate ILP100-Topical in patients with diabetic foot ulcers. Overall, up to 13% of patients with diabetes mellitus of any type develop non-healing ulcers, a physical and psychological disabling condition, where infection of such wound results in a […]

September 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 27 Sep 2022

Protocol for treatment of neurotrophic keratopathy submitted to FDA by ReGenTree

Protocol for a second phase 3 clinical trial for a treatment for neurotrophic keratopathy (NK) – a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, has been submitted. RegeneRx Biopharmaceuticals reported that its U.S. joint venture partner and licensee, HLB Therapeutics, together called ReGenTree, made the submission to the U.S. Food and […]

September 27, 2022 - 3 minutesmins - By Liza Laws

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 27 Sep 2022

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […]

September 27, 2022 - 3 minutesmins - By Liza Laws

News and Trends 27 Sep 2022

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Approval of an investigational new drug (IND) application for mupadolimab has been granted by the Center for Drug Evaluation (CDE) to initiate a phase 1/1b clinical trial in China. Angel Pharma, a clinical stage biopharmaceutical company owns the rights to mupadolimab in Greater China. Mupadolimab is a humanized monoclonal antibody directed against CD73. In preclinical […]

September 27, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Sep 2022

Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke

The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke. Acticor Biotech, a clinical stage biotech company, made the announcement today (September 26). The patient was enrolled at the CHI Memorial Stroke and Neuroscience Center, Chattanooga, Tennessee, by neurologist, Ruchir Shah. Significant potential He said: “I am very […]

September 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Sep 2022

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD’s anti-PD-1 therapy. The […]

September 26, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Everest Medicines gets go-ahead for renal disease drug study

Chinese biopharma company Everest Medicines says the China National Medical Products Administration (NMPA)’s Center for Drug Evaluation has approved the investigational new drug (IND) application for a phase 1b study of EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, in development for the treatment of glomerular diseases. The planned phase 1b clinical study […]

September 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Study data for glioblastoma treatment confirms safety and tolerability profile

The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

Rivus Pharmaceuticals Inc. has completed a $132 million series B financing round. It was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. The financing will further support clinical advancement of lead candidate HU6, a first-in-class controlled metabolic accelerator (CMA) designed […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

A U.S.-based biotech yesterday (September 21) reported additional biomarker results for a treatment of type 2 diabetes (T2D) from a phase 1 study. Glyscend Therapeutics, has been looking at orally administered drug GLY-200, which is a gut-restricted therapeutic. The company also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New […]

September 22, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Treatment for adults with chronic skin condition approved by FDA

Positive results from Eisai and Biogen Alzheimer’s trial

Ilya Pharma enrols first patient in diabetic foot ulcer study

Protocol for treatment of neurotrophic keratopathy submitted to FDA by ReGenTree

Bioheng Biotech has positive CAR-T cell therapy results published in academic journal

Angel Pharma announces approval of IND application for clinical trial of mupadolimab

Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke

TILT and MSD working on immunotherapy trial for non-small cell lung cancer

Everest Medicines gets go-ahead for renal disease drug study

Study data for glioblastoma treatment confirms safety and tolerability profile

Rivus Pharmaceuticals raises $132M for treatment of obesity and cardio-metabolic disorders

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!